Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 2019-04-30 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 2023-06-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 2021-01-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/1/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 8/1/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 8/1/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | +1.26% | - | - | 8.19B | |
| -2.69% | -5.28% | +58.42% | +65.89% | 68.45B | |
| -0.92% | +7.70% | +12.90% | +93.35% | 61.31B | |
| 0.00% | -0.95% | +20.09% | +99.04% | 55.73B | |
| -0.03% | +2.24% | +12.95% | +109.24% | 47.51B | |
| -1.71% | -1.99% | +19.18% | +37.56% | 44.68B | |
| -2.11% | -10.12% | +168.45% | +779.54% | 38.14B | |
| +2.15% | -0.47% | +22.85% | +56.09% | 35.85B | |
| -2.32% | -5.14% | +75.43% | +60.15% | 33.05B | |
| +2.47% | +5.97% | -36.52% | +407.24% | 25.9B | |
| Average | -0.45% | +2.41% | +39.31% | +189.79% | 46B | |
| Weighted average by Cap. | -0.79% | +2.25% | +39.39% | +162.93% |
Employees
355
